Aurinia settles Teva patent suit, bars generic voclosporin launch until Dec. 7, 2036
AUPH•Aurinia settles Teva patent dispute over generic voclosporin
Aurinia Pharmaceuticals settled patent litigation with Teva over a proposed U.S. generic voclosporin 7.9 mg capsule.
Teva stipulated two Aurinia patents expiring in December 2037 are valid, enforceable, and would be infringed by U.S. sales.
The settlement bars a Teva generic launch before Dec. 7, 2036, subject to defined contingencies.
Launch still depends on FDA approval and other cases continue
Any launch also depends on FDA approval for Teva’s abbreviated new drug application.
Separate patent cases continue in New Jersey federal court against other generic challengers.
